Durable CD4+ T-cell Tumor Immunity Following Gene-modified HPSC
基因修饰 HPSC 后的持久 CD4 T 细胞肿瘤免疫
基本信息
- 批准号:8228113
- 负责人:
- 金额:$ 30.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-22 至 2014-02-28
- 项目状态:已结题
- 来源:
- 关键词:Activated LymphocyteAdoptive TransferAdvanced Malignant NeoplasmAllelesAnimal ModelAntigensApplications GrantsAutoantigensAutoimmune ProcessAutoimmunityCD4 Positive T LymphocytesCD8B1 geneCancer VaccinesCharacteristicsDataDevelopmentDifferentiation AntigensEffectivenessEngraftmentEventExperimental DesignsExposure toFrequenciesGene SilencingGene-ModifiedGoalsHLA-DR4 AntigenHealthHelper-Inducer T-LymphocyteHumanImmuneImmune ToleranceImmune responseImmune systemImmunizationImmunologyImmunotherapyInfusion proceduresInterleukin-7KineticsKnock-outLeadLeukocytesLongevityLymphocyteLymphocyte ActivationLymphocyte FunctionMHC Class II GenesMalignant NeoplasmsMediatingMetastatic MelanomaModelingMolecular GeneticsMusPatientsPeripheralPhysiologicalPlayPopulationPositioning AttributeProteinsResearch ProposalsRoleRunningSelf ToleranceStem cell transplantStem cellsSurfaceSystemT-Cell DevelopmentT-Cell ReceptorT-LymphocyteT-Lymphocyte SubsetsTechnologyTestingTherapeuticThymus GlandTransplantationTumor EscapeTumor ImmunityTyrosinase related protein-1Ursidae FamilyVaccinationVitiligoarmbasecancer immunotherapycancer therapyclinical applicationcytokinedesigngene therapyhuman TYRP1 proteinimmune activationimmunogenicityimprovedinnovationmelanocytemelanomanovelnovel therapeuticspublic health relevanceresearch studytumortumor eradication
项目摘要
DESCRIPTION (provided by applicant): Over the past 25 years, cancer immunotherapy has undergone tremendous innovation and progress with developments running parallel to advances in basic immunology, molecular genetics and gene therapy. Many of these treatments which have included potent cytokine infusions, the adoptive transfer of activated lymphocytes, and a wide array of cancer vaccines, have been largely applied to patients with metastatic melanoma. These treatments, however, have been consistently hampered by poor immunogenicity, limited immune durability, immune tolerance and tumor escape. To improve upon existing treatments and to help answer basic questions about mechanisms that fundamentally inhibit immune responses to cancer, we sought to develop a novel translational model of cancer immunotherapy. Supported by our preliminary studies, we focused our experimental efforts on further understanding the effects of antigen expression on lymphocyte selection, immune activation, autoimmunity, and cancer treatment. To investigate these issues, we designed a melanoma-based model composed of four critical components: 1) the use of two different experimental mice, one expressing a human class II allele (HLA-DR4), the other knocked-out in the expression of a melanocyte-differentiation antigen called tyrosinase-related-protein-1 (TRP-1); 2) the study of a crucial subset of T-cells (T-helper cells or CD4+ T-cells) which react against TRP-1; 3) the use of lentiviral technology to deliver to hematopoetic stem cells (HPSC) a CD4+ T-cell receptor (TCR) which reacts against TRP-1; and 4) the transplantation and immune reconfiguration with gene-modified HPSC. To achieve these ends we have broken down the overall goal into three specific aims: 1) Does gene-modified HPSC transplantation lead to competent T-cell development and function and can that functionality be further amplified with supplemental IL-7, vaccination, or by early antigen-driven homeostatic proliferation? 2) Does endogenous TRP-1 expression have a direct impact on immunoselection and immune tolerance following gene-modified HPSC transplantation? 3) What are the autoimmune, anti-tumor effects, and mechanisms-of-action of TRP-1-specific CD4+ T-cells following gene-modified HPSC transplantation? We believe this research proposal builds upon existing treatments and technologies in cancer immunotherapy. What makes this model unique however, is both the role of antigen to control the composition of the T-cell repertoire and the critical position that CD4+ T-cells play in global immune activation and anti-tumor activity. We believe that experimental approaches, which facilitate the long-term engraftment, expansion and activation of highly reactive CD4+ T-cells, ultimately produce more effective cancer immunotherapies. PUBLIC HEALTH RELEVANCE: This research proposal builds upon existing technologies and treatments in gene-therapy and immunotherapy for patients with cancer and metastatic melanoma in particular. Here we demonstrate the development of a model in which we successfully reconfigure the immune system with a specific high-frequency white blood cell that is capable of recognizing a key protein found on the surface of melanoma. We then propose experiments designed to better understand the therapeutic implications of this model, improve its overall effectiveness, and study its mechanisms-of-action.
描述(由申请人提供):在过去的25年中,癌症免疫治疗经历了巨大的创新和进步,其发展与基础免疫学,分子遗传学和基因治疗的进展并行。这些治疗方法包括强效细胞因子输注、活化淋巴细胞的过继性转移和多种癌症疫苗,已主要应用于转移性黑色素瘤患者。然而,这些治疗一直受到免疫原性差、免疫持久性有限、免疫耐受和肿瘤逃逸的阻碍。为了改进现有的治疗方法,并帮助回答有关从根本上抑制癌症免疫反应的机制的基本问题,我们寻求开发一种新的癌症免疫治疗的转化模型。在前期研究的支持下,我们将实验重点放在进一步了解抗原表达对淋巴细胞选择、免疫激活、自身免疫和癌症治疗的影响上。为了研究这些问题,我们设计了一个基于黑色素瘤的模型,由四个关键部分组成:1)使用两只不同的实验小鼠,一只表达人类II类等位基因(HLA-DR4),另一只敲除黑色素细胞分化抗原酪氨酸酶相关蛋白-1 (TRP-1)的表达;2) t细胞(t辅助细胞或CD4+ t细胞)对TRP-1起反应的关键亚群的研究;3)使用慢病毒技术向造血干细胞(HPSC)传递CD4+ t细胞受体(TCR),该受体对TRP-1起反应;4)利用基因修饰的造血干细胞进行移植和免疫重构。为了实现这些目标,我们将总体目标分解为三个具体目标:1)基因修饰的HPSC移植是否导致有能力的t细胞发育和功能,这种功能是否可以通过补充IL-7、接种疫苗或早期抗原驱动的稳态增殖进一步放大?2)内源性TRP-1表达是否直接影响基因修饰HPSC移植后的免疫选择和免疫耐受?3) trp -1特异性CD4+ t细胞在基因修饰的HPSC移植后的自身免疫、抗肿瘤作用和作用机制是什么?我们相信这项研究计划建立在现有的癌症免疫治疗方法和技术的基础上。然而,这个模型的独特之处在于抗原控制t细胞库组成的作用,以及CD4+ t细胞在全球免疫激活和抗肿瘤活性中发挥的关键作用。我们相信,促进高反应性CD4+ t细胞长期植入、扩增和激活的实验方法,最终会产生更有效的癌症免疫疗法。公共卫生相关性:本研究计划建立在现有的癌症和转移性黑色素瘤患者基因治疗和免疫治疗技术和治疗方法的基础上。在这里,我们展示了一种模型的发展,在这种模型中,我们成功地用一种能够识别黑色素瘤表面发现的关键蛋白质的特定高频白细胞重新配置免疫系统。然后,我们提出了旨在更好地理解该模型的治疗意义的实验,提高其整体有效性,并研究其作用机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher E. Touloukian其他文献
Christopher E. Touloukian的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher E. Touloukian', 18)}}的其他基金
Durable CD4+ T-cell Tumor Immunity Following Gene-modified HPSC
基因修饰 HPSC 后的持久 CD4 T 细胞肿瘤免疫
- 批准号:
7735973 - 财政年份:2009
- 资助金额:
$ 30.19万 - 项目类别:
Durable CD4+ T-cell Tumor Immunity Following Gene-modified HPSC
基因修饰 HPSC 后的持久 CD4 T 细胞肿瘤免疫
- 批准号:
8018196 - 财政年份:2009
- 资助金额:
$ 30.19万 - 项目类别:
Durable CD4+ T-cell Tumor Immunity Following Gene-modified HPSC
基因修饰 HPSC 后的持久 CD4 T 细胞肿瘤免疫
- 批准号:
8444280 - 财政年份:2009
- 资助金额:
$ 30.19万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 30.19万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 30.19万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 30.19万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 30.19万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 30.19万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 30.19万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 30.19万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 30.19万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 30.19万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 30.19万 - 项目类别: